Madeline Polak

527 total citations
24 papers, 225 citations indexed

About

Madeline Polak is a scholar working on Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Madeline Polak has authored 24 papers receiving a total of 225 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 9 papers in Pathology and Forensic Medicine and 9 papers in Oncology. Recurrent topics in Madeline Polak's work include Ovarian cancer diagnosis and treatment (8 papers), Advanced Breast Cancer Therapies (7 papers) and Cancer Mechanisms and Therapy (4 papers). Madeline Polak is often cited by papers focused on Ovarian cancer diagnosis and treatment (8 papers), Advanced Breast Cancer Therapies (7 papers) and Cancer Mechanisms and Therapy (4 papers). Madeline Polak collaborates with scholars based in United States, Finland and Brazil. Madeline Polak's co-authors include Marilyn L. Moy, David Gagnon, Caroline R. Richardson, Reema Kadri, Emily S. Wan, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos, Eric Garshick, Joyce F. Liu and Nabihah Tayob and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Madeline Polak

19 papers receiving 224 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Madeline Polak United States	9	87	78	74	42	32	24	225
Lijing Wu China	11	21 0.2×	63 0.8×	144 1.9×	32 0.8×	26 0.8×	20	334
Elodie Coquan France	9	68 0.8×	71 0.9×	48 0.6×	8 0.2×	20 0.6×	37	205
Lanlan Pang China	11	106 1.2×	97 1.2×	84 1.1×	29 0.7×	4 0.1×	31	282
Yuka Murata Japan	9	14 0.2×	31 0.4×	94 1.3×	66 1.6×	16 0.5×	22	299
Guochong Jia United States	7	33 0.4×	65 0.8×	65 0.9×	27 0.6×	8 0.3×	18	233
Natalie Hoog-Labouret France	7	41 0.5×	69 0.9×	37 0.5×	8 0.2×	17 0.5×	24	175
Ana Fröbe Croatia	9	146 1.7×	56 0.7×	55 0.7×	9 0.2×	5 0.2×	41	334
Ehsan Zaboli Iran	9	45 0.5×	105 1.3×	60 0.8×	15 0.4×	3 0.1×	48	283
Stephanie Gutierrez United States	9	57 0.7×	73 0.9×	66 0.9×	36 0.9×	10 0.3×	14	361
Julie Mak United States	7	50 0.6×	39 0.5×	55 0.7×	17 0.4×	55 1.7×	13	213

Countries citing papers authored by Madeline Polak

Since Specialization

Citations

This map shows the geographic impact of Madeline Polak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Madeline Polak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Madeline Polak more than expected).

Fields of papers citing papers by Madeline Polak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Madeline Polak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Madeline Polak. The network helps show where Madeline Polak may publish in the future.

Co-authorship network of co-authors of Madeline Polak

This figure shows the co-authorship network connecting the top 25 collaborators of Madeline Polak. A scholar is included among the top collaborators of Madeline Polak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Madeline Polak. Madeline Polak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Konstantinopoulos, Panagiotis A., Elizabeth K. Lee, Carolyn Krasner, et al.. (2025). Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer. JCO Precision Oncology. 9(9). e2400882–e2400882.

Konstantinopoulos, Panagiotis A., Richard T. Penson, Susana M. Campos, et al.. (2025). Phase 2 study of letrozole, abemaciclib, and metformin in estrogen receptor (ER)–positive recurrent endometrial cancer (EC).. Journal of Clinical Oncology. 43(16_suppl). 5513–5513. 1 indexed citations

Stover, Elizabeth H., Zuzana Tatárová, Sharath K. Bhagavatula, et al.. (2024). Abstract A011: An implantable microdevice to interrogate responses to therapy in ovarian cancer. Cancer Research. 84(5_Supplement_2). A011–A011.

Konstantinopoulos, Panagiotis A., Mingyang Cai, Niya Xiong, et al.. (2024). Serial circulating tumor DNA (ctDNA) sequencing to monitor response and define acquired resistance to letrozole/abemaciclib in endometrial cancer (EC).. Journal of Clinical Oncology. 42(16_suppl). 5592–5592.

Konstantinopoulos, Panagiotis A., Niya Xiong, Carolyn Krasner, et al.. (2024). Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer. Gynecologic Oncology Reports. 52. 101348–101348. 2 indexed citations

Konstantinopoulos, Panagiotis A., Su–Chun Cheng, Elizabeth K. Lee, et al.. (2024). Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses. JCO Precision Oncology. 8(8). e2300635–e2300635. 9 indexed citations

Konstantinopoulos, Panagiotis A., Su–Chun Cheng, Alexandre André Balieiro Anastácio da Costa, et al.. (2023). Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses.. Journal of Clinical Oncology. 41(16_suppl). 5512–5512. 3 indexed citations

Xiong, Niya, Su–Chun Cheng, Madeline Polak, et al.. (2023). A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair–proficient (MMR-P) recurrent or persistent endometrial cancer (EC).. Journal of Clinical Oncology. 41(16_suppl). TPS5628–TPS5628. 1 indexed citations

Lee, Elizabeth K., Andrea E. Wahner Hendrickson, Gerardo Colón‐Otero, et al.. (2023). Abstract B041: A phase 1 study of DS-8201a in combination with olaparib in HER2-expressing malignancies (CTEP #10355): Results of module 1 dose escalation. Molecular Cancer Therapeutics. 22(12_Supplement). B041–B041. 1 indexed citations

10.

Batalini, Felipe, D. Gulhan, Madeline Polak, et al.. (2022). Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers. Clinical Cancer Research. 28(21). 4714–4723. 22 indexed citations

11.

Wan, Emily S., et al.. (2022). Physical Activity, Exercise Capacity, and Body Composition in U.S. Veterans with Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society. 19(10). 1669–1676. 4 indexed citations

12.

Polak, Madeline, et al.. (2022). Performance of bioelectrical impedance analysis compared to dual X-ray absorptiometry (DXA) in Veterans with COPD. Scientific Reports. 12(1). 1946–1946. 14 indexed citations

13.

Stover, Elizabeth H., Niya Xiong, Andrea P. Myers, et al.. (2022). A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma. Gynecologic Oncology Reports. 40. 100974–100974. 13 indexed citations

14.

Robinson, Stephanie A., John A. Cooper, Madeline Polak, et al.. (2021). A randomised trial of a web-based physical activity self-management intervention in COPD. ERJ Open Research. 7(3). 158–2021. 38 indexed citations

15.

Batalini, Felipe, D. Gulhan, Madeline Polak, et al.. (2021). Abstract 156: Mutational signature 3 predicts responses to olaparib plus buparlisib in triple-negative breast cancer and high-grade serous ovarian cancer. Cancer Research. 81(13_Supplement). 156–156.

16.

Konstantinopoulos, Panagiotis A., Alexandre André Balieiro Anastácio da Costa, D. Gulhan, et al.. (2021). A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. Nature Communications. 12(1). 5574–5574. 44 indexed citations

17.

Porter, Rebecca L., Jennifer Veneris, Nabihah Tayob, et al.. (2021). A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) endometrial cancer (EC).. Journal of Clinical Oncology. 39(15_suppl). TPS5611–TPS5611. 3 indexed citations

18.

Xiong, Niya, Nabihah Tayob, Carolyn Krasner, et al.. (2020). LBA35 Phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent/persistent endometrial cancer. Annals of Oncology. 31. S1165–S1165. 11 indexed citations

19.

Wan, Emily S., Madeline Polak, Reema Kadri, et al.. (2020). Long-term effects of web-based pedometer-mediated intervention on COPD exacerbations. Respiratory Medicine. 162. 105878–105878. 34 indexed citations

20.

Polak, Madeline, et al.. (2018). Vitamin D, diet, and lifestyle in a chronic SCI population. Spinal Cord. 57(2). 117–127. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact